Thor Medical ASA (OSL:TRMED) Total Liabilities : kr77.23 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA Total Liabilities?

Thor Medical ASA's Total Liabilities for the quarter that ended in Dec. 2024 was kr77.23 Mil.

Thor Medical ASA's quarterly Total Liabilities increased from Dec. 2023 (kr58.91 Mil) to Jun. 2024 (kr60.20 Mil) and increased from Jun. 2024 (kr60.20 Mil) to Dec. 2024 (kr77.23 Mil).

Thor Medical ASA's annual Total Liabilities increased from Dec. 2022 (kr45.80 Mil) to Dec. 2023 (kr58.91 Mil) and increased from Dec. 2023 (kr58.91 Mil) to Dec. 2024 (kr77.23 Mil).

Thor Medical ASA Total Liabilities Historical Data

The historical data trend for Thor Medical ASA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA Total Liabilities Chart

Thor Medical ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

135.94

156.16

45.80

58.91

77.23

Thor Medical ASA Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															45.80	20.70	58.91	60.20	77.23

Thor Medical ASA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Thor Medical ASA's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	22.9	+	(0.3	+	54.034
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	77.23

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	414.378	-	337.144
	=	77.23

Thor Medical ASA's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	22.9	+	(0.3	+	54.034
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	77.23

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	414.378	-	337.144
	=	77.23

Thor Medical ASA Total Liabilities Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Thor Medical ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (OSL:TRMED) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

0R6Y:UK 8NN:Germany

Address

Karenslyst Alle 9C, Oslo, NOR, 0278

Website

https://www.thormedical.no

Thor Medical ASA is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells.

Thor Medical ASA Headlines

No Headlines